# Situation: A 34-year-old man is admitted with newly diagnosed acute myeloid leukemia (AML). His white blood cell count is 45,000/mm³ with 70% blasts, his hemoglobin is 8.2 g/dL (82 g/L), and his platelet count is 15,000/mm³. Induction chemotherapy is planned. The nurse explains when blood counts are expected to reach their lowest point (nadir) after a dose of conventional cytotoxic chemotherapy. When does the nadir usually occur?

> source: MyMerci (mymerci.kr)  
> url: https://mymerci.kr/pages/nclex_q.php?qn_id=629830  
> language: ko  
> subject: Nursing Practice III — Care of Clients with Problems in Surgery, Oxygenation, Fluid and Electrolytes, Infectious, Inflammatory and Immunologic Response, Cellular Aberrations

## 문제

Situation: A 34-year-old man is admitted with newly diagnosed acute myeloid leukemia (AML). His white blood cell count is 45,000/mm³ with 70% blasts, his hemoglobin is 8.2 g/dL (82 g/L), and his platelet count is 15,000/mm³. Induction chemotherapy is planned.

The nurse explains when blood counts are expected to reach their lowest point (nadir) after a dose of conventional cytotoxic chemotherapy. When does the nadir usually occur?

## 보기

1. 7 to 14 days after the dose **✔ 정답**
2. 15 to 21 days after the dose
3. 1 to 3 days after the dose
4. 4 to 6 weeks after the dose

**정답: 1**

## 해설

Cytotoxic chemotherapy kills rapidly dividing marrow cells, but mature cells already in the blood survive for a time. Counts therefore fall to their lowest point about 7 to 14 days after a dose and recover before the next cycle. This is when infection and bleeding risks are highest.

## 심화 해설

Why the nadir occurs at 7 to 14 days

Conventional cytotoxic chemotherapy targets rapidly dividing cells, which includes the proliferating progenitor cells in the bone marrow. However, mature neutrophils, platelets, and erythrocytes that are already circulating in the peripheral blood are not immediately destroyed by the drug. They continue to survive for their normal lifespan—neutrophils for about 6 to 10 hours in circulation, platelets for roughly 7 to 10 days, and red blood cells for about 120 days. Because the marrow stops producing new cells while the existing mature cells gradually die off, the blood counts decline progressively rather than all at once.

The lowest point, or nadir, is reached when the last cohort of mature cells produced before chemotherapy has disappeared and the marrow has not yet recovered enough to replace them. For most conventional cytotoxic regimens, this occurs approximately 7 to 14 days after the dose. This timing reflects the lifespan of the most short-lived myeloid cells, particularly neutrophils, which are the first lineage to drop and the first to recover.

Key point! The nadir is not the same as the onset of count decline. Counts begin falling within days, but the true lowest point—when infection and bleeding risk peak—is at 7 to 14 days.

Applying this to the AML patient

This patient presents with a white blood cell count of 45,000/mm³ with 70% blasts, hemoglobin of 8.2 g/dL, and platelets of 15,000/mm³. Even before chemotherapy, he is already pancytopenic in the red cell and platelet lines due to marrow replacement by leukemic blasts. Induction chemotherapy will further suppress the remaining normal hematopoietic precursors.

The clinical priority during the expected nadir window of 7 to 14 days is vigilant monitoring for neutropenic fever and bleeding, because both neutrophil and platelet counts will be at their absolute lowest. In AML, the leukemic blast population may also contribute to a misleadingly high total WBC count early on, but functional neutrophils are often scarce. Once chemotherapy clears the blasts and suppresses the marrow, the true depth of neutropenia becomes apparent.

Why the other options are incorrect

| Timing | Why it does not match the nadir |
| --- | --- |
| 1 to 3 days | Too early. Mature circulating cells are still present, so counts have not yet reached their lowest point. This is when decline begins, not when it bottoms out. |
| 15 to 21 days | Too late for most conventional regimens. By this time, marrow recovery is typically underway and counts are rising, unless the regimen is unusually myelosuppressive or the patient has delayed engraftment. |
| 4 to 6 weeks | Far beyond the expected nadir. This timeframe is more consistent with recovery after very intensive conditioning regimens, such as those used before stem cell transplantation, not a single conventional cytotoxic dose. |

What the evidence adds

The pharmacodynamic modeling studies reinforce the same principle. In a multiple-pool cell lifespan model, myelosuppression is described as a function of drug effect on proliferating marrow compartments, while circulating cells are removed according to their intrinsic lifespan . This explains why the nadir is delayed relative to drug administration—the circulating pool must first be depleted by natural senescence.

In patients receiving R-CHOP chemotherapy, prospective monitoring on days 8, 10, and 15 after treatment was used specifically because the hematological nadir was expected within that window . The choice of these assessment days reflects the clinical understanding that the lowest counts cluster around the second week. Similarly, mathematical models of cytarabine-induced myelosuppression in AML track WBC dynamics over time and consistently show a decline phase followed by a nadir and subsequent recovery, with the depth and timing influenced by both drug dose and individual patient factors .

For a patient with AML receiving induction chemotherapy, the period of 7 to 14 days after the dose is when neutropenic precautions, bleeding precautions, and close surveillance for infection must be at their highest intensity. This is not a theoretical point—it directly determines when prophylactic antimicrobials, growth factor support, and transfusion thresholds are most relevant.

## 임상 시나리오

Chemotherapy Nadir MonitoringPeak infection and bleeding risk at 7–14 days
After conventional cytotoxic chemotherapy, blood counts reach their nadir at approximately 7–14 days after the dose. Mature circulating cells survive for their normal lifespan while marrow production is suppressed, so counts fall progressively rather than immediately.

Neutrophils decline first and recover first, making neutropenic precautions most critical during this window. For this AML patient with 70% blasts and platelets of 15,000/mm³, both infection risk and bleeding risk peak at the nadir.

CautionCounts begin falling within days, but the true lowest point is at 7–14 days. Do not mistake early decline for the nadir—monitor for fever, bleeding, and fatigue most closely during this period.

## 핵심 개념

- **nadir** — Lowest point of blood counts after chemotherapy, typically 7–14 days after a conventional cytotoxic dose
- **cytotoxic chemotherapy** — Drugs that kill rapidly dividing cells, including bone marrow progenitor cells
- **neutropenia** — Abnormally low neutrophil count, heightening infection risk at the nadir
- **blast** — Immature leukemic cell; this AML patient has 70% blasts in peripheral blood
- **induction chemotherapy** — Initial intensive treatment aimed at achieving remission in acute leukemia

## 같은 주제 문제

- [Situation: A 52-year-old woman has invasive ductal carcinoma of the left breast, stage IIB…](https://mymerci.kr/pages/nclex_q.php?qn_id=629730)
- [Situation: A 52-year-old woman has invasive ductal carcinoma of the left breast, stage IIB…](https://mymerci.kr/pages/nclex_q.php?qn_id=629731)
- [Situation: A 52-year-old woman has invasive ductal carcinoma of the left breast, stage IIB…](https://mymerci.kr/pages/nclex_q.php?qn_id=629732)
- [Situation: A 52-year-old woman has invasive ductal carcinoma of the left breast, stage IIB…](https://mymerci.kr/pages/nclex_q.php?qn_id=629733)
- [Situation: A 52-year-old woman has invasive ductal carcinoma of the left breast, stage IIB…](https://mymerci.kr/pages/nclex_q.php?qn_id=629734)
- [Situation: A 66-year-old man with adenocarcinoma of the lower rectum undergoes abdominoper…](https://mymerci.kr/pages/nclex_q.php?qn_id=629735)
- [Situation: A 66-year-old man with adenocarcinoma of the lower rectum undergoes abdominoper…](https://mymerci.kr/pages/nclex_q.php?qn_id=629736)
- [Situation: A 66-year-old man with adenocarcinoma of the lower rectum undergoes abdominoper…](https://mymerci.kr/pages/nclex_q.php?qn_id=629737)

---

More free questions: [기출문제](https://mymerci.kr/)

_학습 참고용입니다. 실제 임상은 최신 지침과 소속 기관 프로토콜을 따르세요._